Neuwelt Edward, Abbott N Joan, Abrey Lauren, Banks William A, Blakley Brian, Davis Thomas, Engelhardt Britta, Grammas Paula, Nedergaard Maiken, Nutt John, Pardridge William, Rosenberg Gary A, Smith Quentin, Drewes Lester R
Oregon Health and Science University, Department of Neurology, Veterans Administration Medical Center, Portland, OR, USA.
Lancet Neurol. 2008 Jan;7(1):84-96. doi: 10.1016/S1474-4422(07)70326-5.
There is a paucity of therapies for most neurological disorders--from rare lysosomal storage diseases to major public health concerns such as stroke and Alzheimer's disease. Advances in the targeting of drugs to the CNS are essential for the future success of neurotherapeutics; however, the delivery of many potentially therapeutic and diagnostic compounds to specific areas of the brain is restricted by the blood-brain barrier, the blood-CSF barrier, or other specialised CNS barriers. These brain barriers are now recognised as a major obstacle to the treatment of most brain disorders. The challenge to deliver therapies to the CNS is formidable, and the solution will require concerted international efforts among academia, government, and industry. At a recent meeting of expert panels, essential and high-priority recommendations to propel brain barrier research forward in six topical areas were developed and these recommendations are presented here.
对于大多数神经系统疾病，从罕见的溶酶体贮积病到中风和阿尔茨海默病等重大公共卫生问题，可用的治疗方法都很匮乏。将药物靶向中枢神经系统（CNS）的进展对于神经治疗学未来的成功至关重要；然而，许多潜在的治疗和诊断化合物向脑特定区域的递送受到血脑屏障、血脑脊液屏障或其他特殊的中枢神经系统屏障的限制。这些脑屏障现在被认为是治疗大多数脑部疾病的主要障碍。向中枢神经系统递送治疗方法面临的挑战非常艰巨，解决方案需要学术界、政府和产业界的国际协同努力。在最近一次专家小组会议上，制定了推动六个主题领域脑屏障研究向前发展的重要且高度优先的建议，这些建议在此呈现。
